The major goals of Core C are to support the research activities of this PPG by obtaining, characterizing, and distributing postmortem brain tissues from patients with MSA. The Core will provide detailed neuropathological data from these cases to Core and Project investigators, as well as provide advice and technical support to investigators in this PPG. These goals will be accomplished by the following specific aims: 1. To perform brain autopsies on PPG participants with clinical features of MSA in a timely fashion and according to standard protocol. 2. To provide detailed neuropathologic evaluation to establish a definitive diagnosis and to document the presence or absence of other central (CNS) and peripheral (PNS) nervous system pathologies. Neuropathologic data for all brains will be collected using standardized methods for gross dissection and neurohistology. These approaches include hematoxylin and eosin (H&E), myelin and silver stains, and The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) and Braak scoring, in all cases. Additionally we will immunostain tissues with antibodies to a-synuclein. In cases with Lewy bodies (LB), LBs will be counted in cortical regions to assign a diagnostic category according to the Consortium for Dementia with Lewy Bodies criteria. We will assess the distribution and abundance of GCIs and related LB-like neuronal inclusions, dystrophic synuclein neurites, and other synuclein pathologies in the CNS and PNS of patients with MSA, compared to controls without MSA or any other neurological disease. 3. Collect cerebral spinal fluid (CSF), blood (huffy coat), and blood-spot samples on all cases. CSF and huffy coat samples will be frozen and banked for future research studies. 4. Store brain tissue and CSF, blood (buffy coat), and blood spot samples and provide pathologically well-characterized tissue samples for on-going research (Projects 2, 3, and Core D). 5. Monitor the acquisition and distribution of these tissue samples using a computerized database and maintain a computerized archive of histopathologic findings for research use by investigators in this PPG. 6. Provide advice and technical support to facilitate studies by PPG investigators on synucleinopathies and synucleinopathy models, especially Projects 2 and 3. 6. Prepare and store DNA from MSA patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Program Projects (P01)
Project #
5P01NS044233-10
Application #
8740564
Study Section
Special Emphasis Panel (ZNS1-SRB-E)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
10
Fiscal Year
2014
Total Cost
$91,579
Indirect Cost
$32,920
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Loavenbruck, Adam J; Singer, Wolfgang; Mauermann, Michelle L et al. (2016) Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? Ann Neurol 80:401-11
Valera, Elvira; Spencer, Brian; Masliah, Eliezer (2016) Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics 13:179-89
Labbé, Catherine; Heckman, Michael G; Lorenzo-Betancor, Oswaldo et al. (2016) MAPT haplotype diversity in multiple system atrophy. Parkinsonism Relat Disord 30:40-5
Spencer, Brian; Williams, Stephanie; Rockenstein, Edward et al. (2016) α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease. Ann Clin Transl Neurol 3:588-606
Spencer, Brian; Kim, Changyoun; Gonzalez, Tania et al. (2016) α-Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Hum Mol Genet 25:1100-15
Valera, Elvira; Masliah, Eliezer (2016) Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord 31:225-34
Valera, Elvira; Masliah, Eliezer (2016) Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem 139 Suppl 1:346-352
Valera, E; Monzio Compagnoni, G; Masliah, E (2016) Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy. Neuropathol Appl Neurobiol 42:95-106
Mandler, Markus; Valera, Elvira; Rockenstein, Edward et al. (2015) Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener 10:10
Low, Phillip A; Reich, Stephen G; Jankovic, Joseph et al. (2015) Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol 14:710-9

Showing the most recent 10 out of 145 publications